– USA, OH – Nordson Corporation (NASDAQ: NDSN) today announced the appointment of Dr. Milton Morris to its Board as Independent Director, bringing robust business leadership experience, as well as a legacy of successful product innovation, to the board.
“We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson’s strength in understanding customer needs and bringing diversified precision technology solutions to the market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further expand acquisitively in this exciting space. We look forward to bringing Milton’s perspective to the board,” said Board Chair, Michael Merriman.
Dr. Morris will also join the audit committee.
About Dr. Milton Morris
Dr. Morris has demonstrated a passion for product development that improves people’s lives throughout his career. He has also led decentralized organizations, growing successful businesses and cultivated diverse and inclusive talent pipelines.
“I look forward to partnering with the Nordson board of directors and executive management team. The company is making solid progress on its Ascend strategy to achieve top-tier growth with leading margins and returns. I am excited to reinforce their strong commitment to innovation while also sharing my unique perspective from the medical device industry,” said Dr. Morris.
Dr. Morris retired in 2022 from Neuspera Medical Inc., a privately held, venture-backed, clinical-stage neuromodulation company committed to developing implantable medical device technology focused on improving patients’ lives battling chronic illness or dysfunction. He has served as president and CEO of Neuspera since 2015. Dr. Morris currently serves as a Principal of MEHL BioMedical, LLC, where he has provided consulting services to start-up companies in the biomedical device industry since 2015. He previously was SVP, research and development of Cyberonics, Inc., maker of the Vagus Nerve Stimulation System from 2009 through 2014. His prior work experience also includes serving as a director, program management and operations of InnerPulse, Inc., a developer of the technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias, as well as director, marketing and arrhythmia franchise leader of Boston Scientific Corporation (NYSE: BSX), a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties. He serves as a director on the boards of Embecta Corp. (Nasdaq: EMBC) and Myomo, Inc. (NYSE: MYO).
About Nordson Corporation
Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top-tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries.
For more information: https://www.nordson.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
